Shares of Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) have earned an average recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $24.14.
A number of research analysts recently issued reports on IMMX shares. Bank of America started coverage on shares of Immix Biopharma in a report on Thursday, June 18th. They issued a “buy” rating and a $27.00 price objective for the company. Morgan Stanley cut their price target on shares of Immix Biopharma from $20.00 to $19.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. HC Wainwright boosted their price objective on shares of Immix Biopharma from $20.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. Citigroup restated a “market outperform” rating on shares of Immix Biopharma in a report on Wednesday. Finally, Mizuho raised their target price on Immix Biopharma from $15.00 to $26.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 15th.
Get Our Latest Stock Analysis on Immix Biopharma
Immix Biopharma Trading Down 1.6%
Immix Biopharma (NASDAQ:IMMX – Get Free Report) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). On average, equities research analysts forecast that Immix Biopharma will post -0.75 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in IMMX. Opaleye Management Inc. acquired a new stake in Immix Biopharma during the second quarter worth approximately $24,177,000. Engineers Gate Manager LP bought a new position in shares of Immix Biopharma during the 2nd quarter worth approximately $184,000. Squarepoint Ops LLC grew its position in shares of Immix Biopharma by 57.5% during the 2nd quarter. Squarepoint Ops LLC now owns 70,062 shares of the company’s stock worth $722,000 after buying an additional 25,572 shares during the period. Compass Financial Management LLC acquired a new stake in shares of Immix Biopharma during the 2nd quarter worth approximately $62,000. Finally, Velan Capital Investment Management LP increased its stake in shares of Immix Biopharma by 46.6% in the 2nd quarter. Velan Capital Investment Management LP now owns 1,085,000 shares of the company’s stock valued at $11,186,000 after acquiring an additional 345,000 shares in the last quarter. 11.26% of the stock is owned by institutional investors and hedge funds.
About Immix Biopharma
Immix Biopharma, Inc (NASDAQ: IMMX) is a clinical-stage biopharmaceutical company developing cell therapies for cancer and autoimmune diseases. The company focuses on treatments designed to target disease-associated cells and address serious conditions with limited therapeutic options.
Its lead product candidate is NXC-201, an autologous chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA). NXC-201 is being investigated for relapsed or refractory AL amyloidosis and multiple myeloma, two diseases involving abnormal plasma cells.
Recommended Stories
- Five stocks we like better than Immix Biopharma
- Everyone in AI Is Quietly Copying Palantir’s Playbook
- Advanced Micro Devices Is Spending $8.2 Billion to Learn What AI Needs Next
- JPMorgan Bets on Genius Sports as the Market Loses Patience
- Apple’s $5.7 Billion Patent Verdict Raises a Bigger Royalty Question
Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
